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Background
The etiology and risk factors associated with gastrointestinal bleeding (GIB) in
patients with continuous-flow left ventricular assist devices (CF-LVADs) are
currently unknown. Therefore, we sought to assess the risk factors for GIB in these
patients.
Design and Methods
This was a retrospective, non-randomized, non-controlled study at a single center.
Between 2012 and 2014, 65 men and 6 women (mean age = 55 ± 12 years)
underwent CF-LVAD implantation at our institution. Overall, 23.9% of patients
(17/71) had at least one GIB episode. Endoscopy confirmed GIB in 13/17.
Arteriovenous malformation was the major GIB source in 8/13 (61%). There was
no significant difference in incidence of GIB with regard to INTERMACS profile,
blood type, or device type—HeartWare vs. HeartMateII. All our patients with GIB
were men, most had hyperlipidemia, and most likely had ischemic cardiomyopathy

The VAD Journal: https://doi.org/10.13023/VAD.2016.22

Page 1 of 14

The VAD Journal: The journal of mechanical assisted circulation and heart failure

(65%) and peripheral vascular disease (24%). The only significant risk factor for
GIB was chronic kidney disease (odds ratio= 3.95; 95% confidence interval of 1.21
to 12.84; p=0.02). At the time of the first GIB, mean hemoglobin was 7.38 ± 1.06
g/dl, international normalized ratio was 2.08 ± 0.69 IU, and mean arterial pressure
was 75 ± 12 mmHg. Ten patients (59%) required hospital admission for treatment.
Conclusion
In our patients GIB was often a single event and often occurred within first month
after implantation. Prevention strategies should be focused on this vulnerable
period, especially in patients with chronic kidney disease
Keywords: gastrointestinal bleeding, left ventricular assist device (LVAD), heart
failure, thromboembolic event

Introduction
The use of a left ventricular assist device (LVAD) either as a bridge to
transplantation or a destination therapy has significantly improved survival for endstage heart failure patients.1,2 The new generation of continuous flow devices have
favorable characteristics; they are small, durable, and are associated with fewer
adverse events than pulsatile LVADs. Nevertheless, important comorbidities
associated with these devices do exist, and they are partly related to bleeding
diathesis. Bleeding complications following LVAD implant are common and
contribute significantly to morbidity and mortality. Overall bleeding rates are in the
range of 45% to 55% with gastrointestinal bleeding (GIB) occurring in
approximately 25% of patients with LVADs.1,3-6 This results in hospital
readmissions and treatment, which increases the total cost of care considerably.
It has been suggested that reduced pulse pressure induced by CF-LVADs results
in hypoperfusion of the gastrointestinal mucosa and neovascularization in friable
vessels that are prone to bleeding.7 These gastrointestinal angiodysplastic
conditions are found at increased rates in patients after CF-LVAD implantation.4,8
The high incidence of bleeding has also been attributed to the development of
acquired von Willebrand syndrome (AVWS), which is a deficiency of the high
molecular weight von Willebrand multimers (HMWM).9,10 The shear forces on
blood components created by continuous flow LVADs damage and inactivate
HMWM. The complex interaction between a patient's innate hemostatic
characteristics, anatomical predisposition for bleeding, AVWS, and anticoagulation
therapy all contribute to the development of the bleeding complications.11
Management of GIB requires alteration of anticoagulation and antiplatelet therapy,
consequently complicating the already altered thrombotic profile and increasing
the risk of thromboembolic (TE) events, including pump thrombosis.5
The aim of this study was to identify the characteristics of patients who had
undergone implantation of a CF-LVAD and had experienced nonsurgical GIB
events. We sought to evaluate risk factors that make these patients prone to GIB
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and determine their additional TE hazard in order to improve management of this
complication.

Methods
Study Population
This single-center retrospective study included 71 patients (65 men and 6 women)
underwent implantation of a CF-LVAD; HeartMate II (Thoratec Corporation,
Pleasanton, CA) (HMII) 50 patients, and HVAD (HeartWare Inc., Framingham,
MA) in 21 patients. Pre-operative clinical characteristics were recorded for all
patients and included INTERMACS profile, presence of coronary artery disease,
peripheral vascular disease, diabetes, presence of a known GI disease, prior
stroke, chronic kidney disease, atrial fibrillation, hypertension, and hyperlipidemia.
The Institutional Review Board approved the study and all patients gave informed
consent for participation.
After LVAD implantation, patients were started on intravenous heparin and
transitioned to oral anticoagulation therapy with warfarin between postoperative
days 2 and 5. Thereafter, all patients received 81mg aspirin and warfarin to
achieve the target INR of 2–3 IU. Additional antiplatelet therapy with 75mg
dipyridamole 3 times per day was given in 2 of 71 patients who had developed
device thrombosis. Platelet function was monitored by light transmittance
aggregometry in all patients pre-operatively and during bleeding episodes. The
pump speed setting of both devices was determined by ramp speed
echocardiogram studies. During the first 24 hours after implantation in patients
with the HMII, pump speed was increased under echocardiographic guidance up
to 8800 revolutions per minute (RPM) to allow aortic valve opening with a ratio of
1:3. In HVAD-supported patients, pump speed was increased up to 2800 RPM.
Later, pump speed was optimized on the basis of patient symptoms, suction
events, and echocardiographic evaluation.
Outcome Assessment
Major bleeding was defined as an episode of suspected internal bleeding resulting
in transfusion of packed red blood cells (RBCs), hospitalization, surgical
intervention, or death.7 In specific cases, GIB was defined by clinical evidence of
bleeding (guaiac-positive stool, melena, hematemesis, hematochezia, or the
presence of blood in the GI tract on endoscopic evaluation) with a decrease in
hemoglobin (Hb)≥ 2 g/dl compared to the patient’s Hb value at the time of the last
follow-up. Multiple bleeding events during the same hospitalization were counted
as the same event. Patients underwent upper endoscopic examination
(esophagogastroduodenoscopy or small-bowel enteroscopy) in the presence of
melena and/or hematemesis and underwent colonoscopy when presenting with
hematochezia and medically stable. Gastrointestinal bleeding was categorized as
upper GIB, proximal to the ligament of Treitz, or lower GIB, distal to the ligament of
Treitz.

The VAD Journal: https://doi.org/10.13023/VAD.2016.22

Page 3 of 14

The VAD Journal: The journal of mechanical assisted circulation and heart failure

Anticoagulation therapy was discontinued until active GIB stopped. The decision to
restart anticoagulation therapy was based on clinical assessment after the
remission of active GIB. Treatment options for bleeding vessels were endoclips
with epinephrine injections or cauterization (argon plasma coagulation or gold
probe cauterization). Additionally, medical gastro-protective therapy with proton
pump inhibitors was utilized.
We also analyzed patients on LVAD support for thromboembolic (TE) events
(stroke, transient ischemic attack, and confirmed or suspected pump thrombus),
hemolysis, right heart failure, respiratory failure, renal and hepatic dysfunction, and
survival. The primary goal of this study was to analyze the frequency of GIB as
well as the location and etiology of GIB in both LVAD groups. The frequency of TE
events was analyzed as well. Median follow-up and LVAD support was 6 months
(3 to 23months).
Statistical Analysis
Data analysis used SPSS 22.0 statistical software (SPSS, Inc., Chicago, IL), and
values are expressed as mean ± standard deviation for normally distributed data
or as medians with ranges for non-normally distributed continuous data.
Categorical data are presented as percentages. Student’s t-test and the
independent samples Mann–Whitney test for continuous variables or the chisquare test for categorical data were used to compare data between the two
groups. Fisher’s exact test was used when appropriate. Logistic regression
analysis was used to identify risk factors for GIB. A p value <0.05 was considered
statistically significant.
Results
Twenty-five GIB episodes were recorded in the 17/71 (23.9%) patients. Patients
with GIB were all men, with a mean age of 59 ± 8 years. Median time to the first
GIB episode was 21 days (range, 11 to 140 days), with 11/17 episodes occurring
within first month after the pump implantation. Fourteen patients had a single
episode, and 3 patients had multiple bleeding episodes (3, 4, and 4 bleeding
episodes, respectively). The second bleeding episode occurred 20, 24 and 110
days after the first bleeding episode, respectively. All patients with multiple GIBs
had HMII pump.
Preoperative data for patients with GIB and those without are shown in Table 1. In
patients with GIB, significantly more patients had chronic kidney disease, and
more patients had hyperlipidemia, but the latter difference did not reach
significance. Two patients had known past medical history of GI peptic ulcers. On
logistic regression analysis, the only risk factor significant for GIB was the
presence of chronic kidney disease (odds ratio=3.95; 95% confidence interval of
1.21 to 12.84; p=0.02).
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Table 1. Baseline Patient Characteristics
Age (year)
Men/women
Body mass index (kg/m 2)
Heart disease
Ischemic cardiomyopathy
Idiopathic cardiomyopathy
Diabetes mellitus
Hypertension
Hyperlipidemia
Myocardial infarction
Peripheral vascular disease
Chronic kidney disease
Atrial fibrillation/flutter
Chronic obstructive pulmonary dis.
Stroke
GI ulcer
LV ejection fraction (%)
LV end-diastolic dimension (cm)
Mean arterial pressure (mmHg)
Sodium (mEq/L)
Blood urea nitrogen (mg/dl)
Creatinine (mg/dl)
AST (IU/L)
ALT (IU/L)
Total bilirubin (mg/dl)
Albumin (g/dl)
INR (IU)
Device
HVAD
HMII
BTT/DT
Intensive care unit stay (days)
Pre-implantation support
ECMO
IABP
TandemHeart
Blood type
O
A
B
AB
INTERMACS score
1
2
3
4-7

GIB (N=17)
59 ± 8
17/0
29.1 ± 6.3

Non-GIB (N=54)
54 ± 13
48/6
29.9 ± 7.0

11 (65)
6 (35)
12 (71)
14 (82)
12 (71)
9 (53)
4 (24)
11 (65)
8 (47)
2 (12)
4 (24)
1 (6)
19 ± 5
6.8 ± 0.8
88 ± 14
137 ± 4.0
29.8 ± 17
1.83 ± 1.4
30 (17–203)
36 (20–289)
0.8 (0.4–10.7)
2.9 ± 0.63
1.2 ± 0.2

27 (50)
27 (50)
28 (52)
45 (83)
23 (43)
25 (46)
5 (9)
16 (30)
17 (32)
6 (11)
4 (7)
1 (2)
20 ± 7
6.5 ± 1.2
82 ± 12
137 ± 4.9
31.7 ± 19
1.62 ± 0.8
34 (4–789)
36 (8–1574)
1.0 (0.4–120)
3.02 ± 0.55
1.4 ± 0.6

6 (35)
11 (65)
14/3
9±5

15 (28)
39 (72)
28/26
16 ± 18

0 (0)
3 (18)
2 (12)

5 (9)
10 (19)
7 (13)

9 (53)
5 (29)
3 (18)
0 (0)

27 (50)
15 (28)
9 (17)
3 (5)

5 (29)
7 (41)
3 (18)
2 (12)

20 (37)
13 (24)
16 (30)
5 (9)

p Value
0.145
0.151
0.699
0.289

0.174
0.925
0.055
0.632
0.123
0.019
0.241
0.941
0.067
0.381
0.343
0.476
0.163
0.807
0.713
0.430
0.558
0.848
0.327
0.631
0.383
0.554

0.026
0.321
0.189
0.910
0.877
0.805

0.231

Results are presented as mean ± standard deviation, median (range), or number of
patients (%).
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Abbreviations: GIB, gastrointestinal bleeding; ALT, alanine amino transferase; AST,
aspartate amino transferase; BTT, bridge-to-transplant; DT, destination therapy; ECMO,
extracorporeal membrane oxygenation; GI, gastrointestinal; HMII, HeartMate II; HVAD,
HeartWare; IABP, intra-aortic balloon pump; INR, international normalized ratio; LV, left
ventricle.

All patients with GIB presented with anemia — also, 8 with melena, 1 with
hematemesis, 6 without obvious bleeding source, and 2 with only positive guaiac
stool test. Esophagogastroduodenoscopy (EGD), small-bowel enteroscopy, and
colonoscopy confirmed bleeding sources in 13 patients. Arteriovenous
malformations (AVMs) were identified as the major source of bleeding in 8/13
patients (61%). The location of the first incidence of GIB is summarized in Table 2.
Table 2. Location of the First Gastrointestinal Bleeding Event after Left
Ventricular Assist Device Implantation
Location

N

Upper GI

9

Mallory–Weiss tear

1

Gastric AVM

2

Gastric ulcer

1

Gastric polyp

1

Duodenal AVM

2

Jejunal AVM

2

Lower GI

6

Cecal AVM

1

Cecal ulcer

1

Distal transverse colon ulcer

1

Sigmoid colon diverticulosis

1

Sigmoid colon AVM

1

Rectal AVM

1

Abbreviations : GI – gastrointestinal, AVM-arteriovenous malformations
In 2 patients endoscopy confirmed bleeding from 2 sources during the same GIB
episode. One patient had both gastric and jejunal AVM. The other patient had
rectal AVM and sigmoid colon diverticulosis. In 1 patient, the small bowel AVM
was identified only by on-table push enteroscopy because EGD, colonoscopy,
nuclear medicine study, and angiograms failed to diagnose the bleeding source.
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GI endoscopy was not performed in 2 patients—1 with melena and 1 without
obvious bleeding source—due to hemodynamic instability. In another 2 patients,
conclusions were made by guaiac-positive stool tests only. These 4 patients
experienced single bleeding episodes. For the 17 patients with GIB, characteristics
at the time of the first bleeding episode are shown in the Table 3. All patients had
body mass index (BMI)>18.5kg/m2 at the time of the GIB. Patients with multiple
GIBs displayed trends toward higher INR values, lower PTT values, and lower
creatinine levels (Table 4). Only 1 patient with multiple GIB episodes was
diagnosed with coagulopathy (factor deficiency in the common or in both intrinsic
and extrinsic pathways), and one patient had GIB whenever his INR value
exceeded 2IU.
Table 3. Patient Characteristics at the Time of the First Gastrointestinal
Bleeding Event
GIB (N=17)
7.38 ± 1.06
2.08 ± 0.69
23.21 ± 5.81
48.15 ± 12.5
232 ± 98
33 ± 15
2.02 ± 1.33
2.35 ± 0.49
75 ± 12
1.65 ± 0.52

Hemoglobin (g/dl)
INR (IU)
Prothrombin time (s)
Partial thromboplastin time (s)
Platelet count
Blood urea nitrogen (mg/dl)
Creatinine (mg/dl)
Albumin (g/dl)
Mean arterial pressure (mmHg)
Discharge INR (IU)

Results are presented as median (range), mean ± standard deviation, or number
(%).
Abbreviations: N, number of patients with gastrointestinal bleeding; INR,
international normalized ratio; RBC, red blood cells.
Table 4. Characteristics of Patients with Single and Multiple GIB
Parameter
INR (IU)
Partial thromboplastin
time (s)
Creatinine (mg/dl)
Albumin (g/dl)
Right heart dysfunction
(n)

Single GIB (N=14)

p Value

1.86 ± 0.5
49 ± 11

Multiple GIB
episodes (N=3)*
2.49 ± 1.33
36 ± 14

2.4 ± 1.6
2.34 ± 0.5
11

1.4 ± 0.3
2.23 ± 0.7
1

NS
NS
NS

NS
NS

Abbreviations: NS, not significant; GIB, gastrointestinal bleeding; INR, international
normalized ratio.* Average of all episodes.
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Of the 17 patients with GIB, 7 were hemodynamically stable (MAP> 70 mmHg,
Hb≥ 7.0 g/dl, and INR <3.5 IU) when presenting at hospital. The other 10 required
additional medical management for hemodynamic instability while hospitalized.
LVAD operating parameters at the time of GIB episode and at 30-day follow-up are
shown in Table 5.
Table 5. LVAD Operating Parameters at 30-Days after LVAD Implant and at
the First GIB Episode
Patients without
GIB at 30 days
on LVAD

HMII
Pump
(RPM)

speed

8400
9000)

N=39
(7990–

Patients with GIB
at 30 days on
LVAD

8800
9000)

N=11
(8200–

Patients with GIB
at first GIB
episode

8400
9000)

N=11
(8000–

p
Value

0.069

Pump flow (LPM)

5 (2.9–8.5)

4.8 (4.3–6.3)

5.5 (4.4–7.7)

0.876

Pump power (W)

4.8 (3.9–6.8)

5 (4.3–6.9)

5.4 (4.1–7.5)

0.113

Pulsatility index

6.2 (4–8)

5.6 (3.8–8.7)

6.1 (3.8–8.6)

0.626

Pulsatility (y)

14

3

11 (58)

0.828

MAP (mmHg)

78 ± 11

78 ± 10

78 ± 12

0.741

N=15
2500
(2400–
2800)

N=6
2580
(2500–
2600)

N=6
2560
(2500–
2600)

Pump flow (LPM)

5 (3.8–7.3)

5.5 (5.0–6.2)

4.9 (4.6–5.7)

0.387

Pump power (W)

3.4 (2.7–4.8)

3.7 (3.0–4.0)

3.4 (3.2–3.4)

0.765

Pulsatility index

n/a

n/a

n/a

n/a

Pulsatility (y)

9

4

0

0.023

MAP (mmHg)

75 ± 8

77 ± 10

70 ± 12

0.701

HVAD
Pump
(RPM)

speed

0.467

Results are presented as median (range), mean ± standard deviation, or number.
N, number of patients.
n/a, not applicable.
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Abbreviations: GIB, gastrointestinal bleeding; HMII, HeartMate II; HVAD,
HeartWare; LPM, liters per minute; RPM, revolutions per minute; MAP, mean
arterial pressure.
Patients with multiple GIB episodes received, on average, 3.5 units of RBCs plus 2
units of fresh frozen plasma (FFP) at the second bleeding episode and 2.5 and 2
units of RBCs at the third and fourth bleeding episode, respectively. There were no
platelet transfusions or cryoprecipitate transfusions. After discharge from the first
GIB episode, the majority of patients were restarted on both aspirin and warfarin
therapy (92%), with only 1 patient restarted on triple warfarin-aspirin-dipyridamole
therapy.
There were 3 TE events in our group of patients with GIB: 1 transient ischemic
attack 345 days after device implantation, 1 stroke 53 days after device
implantation, and 1 confirmed device thrombosis 86 days after LVAD placement.
Two patients had thromboembolic events at 26 days and 24 days after the GIB
event. The first patient had multiple GIB events and was receiving only aspirin at
the time of the event. He subsequently underwent heart transplantation for device
thrombosis (not pump replacement). In total 3 patients with GIB underwent heart
transplantation. One patient with GIB died of multiple organ failure within 30 days
after LVAD implantation.

Discussion
In summary, pump thrombosis has been and continues to remain a major adverse
event during destination therapy. Pump thrombosis may have been initially
underestimated. Aggressive monitoring of anticoagulation and hemolysis is the
sine qua non of pump thrombosis prevention. We observed GIB complications in
nearly 25% our patients supported with CF-LVADs, with no difference between the
types of LVADs. AVMs were the most common etiology. Overall, patients with and
without GIB had similar pre-implantation characteristics, perioperative adverse
events, and survival rates. The majority of our patients with GIB received LVAD
support as a bridge to transplant, and they were not statistically older than patients
without GIB, which has been recognized as a risk factor in previous studies.12 The
only patient characteristic that was significantly associated with GIB was the
presence of chronic renal insufficiency. This has been linked with nonsurgical
bleeding in different clinical settings.7,12,13 . All our patients with GIB were male,
most had hyperlipidemia, and most likely had ischemic cardiomyopathy (65%) and
peripheral vascular disease (24%).
Previously, it has been shown that patients with O blood type have lower levels of
measured von Willebrand factor and factor VIII.15 However, in our study group, the
presence of blood type O was not associated with increased risk of bleeding. In
88% of our patients, bleeding events occurred in the absence of supratherapeutic
anticoagulation, with no patient having an INR> 4.7,14 No abnormality was
observed in baseline platelet function of patients with GIB. The AVWS, LVAD
pump speed, lack of pulsatility, and platelet aggregation have been implicated in
the increased incidence of bleeding in CF-LVADs. In our study group, HMWMs
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were not routinely measured, but recently published papers show that AVWS is
found in all patients with CF-LVADs.16-18
Treatment for GIB involves decreasing INR goals and withholding antiplatelet and
anticoagulation medications. This places the patient at increased risk of TE events
while on VAD support.19,20 The patient with documented pump thrombus in our
study previously had multiple GIB events and was receiving only 81mg aspirin at
the time of thrombosis. Patients with stroke and TIA had both anticoagulation and
antiplatelet therapy at the time of their TE events. Our institutional policy for
anticoagulation and antiplatelet therapy after the first GIB event is warfarin with
81mg aspirin and a target INR of 1.5–2. If there is recurrence of GIB after the first
event, patients will still receive warfarin to achieve a target INR of 1.5–2 but
without any antiplatelet therapy. After a third event, patients are discharged with all
anticoagulation and antiplatelet therapy withheld.
For patients with multiple GIB events, testing for coagulopathy should be utilized
as an additional diagnostic measure to determine desirable INR in that
subpopulation of LVAD recipients. It was shown that LVAD patients have an
increase in activated endothelial cells, which leads to expression of inflammatory
markers that can promote coagulopathies in addition to the hypercoagulable state
and predisposition of platelet activation due to direct contact between blood and
the foreign material of the LVAD.3,21 Patients with multiple GIB events when
INR>2IU helped us determine our institutional policy for anticoagulation and
antiplatelet therapy after the bleeding event. Prior to bleeding events, our patients
are generally prescribed warfarin with INR goals of 2–3, but therapy is often
discontinued after patients experience GIB and is then restarted after GIB
resolves. None of the confirmed GIB events were fatal in our study group.
It has been hypothesized that a lower pump speed in an LVAD may result in
higher pulse pressures and fewer GIB events.22 Conversely, higher pump speed
may result in decreased capillary pressure and ischemia in the GI mucosa in
addition to AVWS.21 Also, a lower LVAD pump speed may cause less dispersal of
heat and increased propensity for clot formation.23 In theory, the HVAD contactfree design and lower pump speed should provide cardiac support with lower
levels of sheer stress, preserving HMWM.16,17 Although the HVAD pump speed is
low, it still reaches a sufficient threshold to induce von Willebrand factor unfolding
and loss of HMWM, with higher speed corresponding to greater loss of
HMWM.16,17 The association between severe right ventricular (RV) dysfunction and
increased bleeding risk could also be related to a more advanced stage of heart
failure.7 Patients with severe RV dysfunction can present clinically with low LVAD
flows and low pulsatility index, which could additionally explain the association
between RV dysfunction and bleeding risk.7 Similarly, severe RV dysfunction and
portal hypertension are associated with malnutrition, and abnormal liver function
increases risk of bleeding.24,25 It should be noted that the sample size in this study
may have limited the study’s ability to detect statistically significant differences in
some of the variables compared. Similarly, this study consisted of patients
receiving LVAD support mainly as bridge-to-transplant therapy, which may have
selected for certain patient characteristics. Also, von Willebrand factor multimers
were not routinely measured. Future prospective multicenter trials are still needed
to further assess the mechanisms of GIB and TE events.
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As the number of patients receiving LVAD support grows worldwide, it is expected
that adverse bleeding events will increase, with a significant increase of cost for
patient hospitalization and management.1,7 For these patients, standard upper
endoscopy and colonoscopy, offered as diagnostic and therapeutic medical
procedures, as well as video capsule or surgical push enteroscopy can be
performed in an outpatient setting with gastrointestinal protective therapy (proton
pump inhibitors), interruption of warfarin therapy, and iron supplements. Afterward,
a new regimen for anticoagulation therapy can be designed for the patient.
Patients requiring blood transfusion, FFP, cryoprecipitate, or Vitamin K antagonist
therapy would be managed in an outpatient setting as well. Management of these
patients with such a plan requires a team-based approach and good coordination
among cardiologists, gastroenterologists, and hematologists in an outpatient
setting.
This was a retrospective, non-randomized, non-controlled study at a single center.
The limited sample size and patient characteristics make comparison to other
reports difficult. Although the percentage of patients with GIB was comparable to
other studies, the median time to the first GIB event in our study was only 21
days—considerably earlier than other reports.20,26 However, other studies have
shown that the time to first GIB is as soon as 8 days27 and as long as 383 days28,
and the range in our study was 11 to 140 days. Although we did not investigate
this phenomenon, we suspect that some factors that may influence the time to first
GIB are severity of illness, renal disease, age, gender, anticoagulation and
antiplatelet therapy, prior GI pathology and degree of AVWS. More studies are
needed to better understand both the time of first GIB and the time to recurrence
of GIB.
In conclusion, GIB occurs mainly as a single event that is widely variable in timing,
but may present within the first month after surgery. Therefore, prevention
strategies should be focused on this vulnerable post-implantation period,
especially in patients with chronic kidney disease.
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